IVD Antibody Development Services for Matrix MMP-9 Marker

Creative Biolabs is a leading service provider that focuses on polyclonal, monoclonal, and recombinant antibody development for research, diagnosis, and potential therapeutics. Based on our extensive experience and state-of-the-art platforms, Creative Biolabs now offers a series of biomarker-specific IVD (in vitro diagnostic) antibody development services to clients globally. Especially, we introduce our IVD antibody development services for MMP-9 marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.

Matrix metalloproteinases (MMPs), a family of structurally similar endopeptidases, are able to degrade the whole components of the extracellular matrix (ECM). Due to the substrate specificity and existence of a transmembrane domain, MMPs are classified into three types: collagenases gelatinases, stromelysins and membrane type. These enzymes share structural homology, comprising a zinc atom at the catalytic site, and are restrained by specific inhibitors. The majority of MMPs need activation by proteolytic cleavage, and a few proteases act an essential role in this process. MMP-9 is one of the most extensively studied MMPs, modulates pathological remodeling processes, such as inflammation and fibrosis in cardiovascular disease. It directly degrades ECM proteins and stimulates cytokines to modulate tissue remodeling. Besides, deletion or inhibition of MMP-9 has displayed overall beneficial in a variety animal models of cardiovascular disease.

Figure 1. Schematic diagram of the neutrophil roles in inflammation and MMP-9 release. MMP-9 plays an essential role in the regulation of inflammation and fibrosis in cardiovascular disease. (Yabluchanskiy, A. 2013)

MMP-9 Marker of Myocardial Ischemia

MI is an acute condition characterized by irreversible myocardial tissue damage which arises after continuous disruption of blood supply to the myocardium. It is identified by raised inflammation that takes the place of necrotic tissue with a fibrotic scar. Previous studies have reported that MMP-9 robustly improved during many cardiovascular diseases, such as MI, hypertension and atherosclerosis. It has also demonstrated that higher MMP-9 levels serve a crucial role during the early stages of acute MI and development to heat failure, when presented in decompensated patients. Meanwhile, MMP-9 levels increase as early as a few minutes post-MI and keep improved for the first week in a number of animal models of MI. Therefore, MMP-9 is suggested as a potential biomarker for the diagnosis of MI.

Figure 2. Part A shows the MMP-9 involvement in the atherosclerosis and part B shows the MMP-9 involvement in MI. (Yabluchanskiy, A. 2013)

MMP-9 Marker of Acute Ischemic Stroke

Ischemic stroke is a condition sudden reduced of blood circulation to an area of the brain, leading to a corresponding loss of neurologic function. AIS is induced by thrombotic or embolic occlusion of a cerebral artery and is more general than hemorrhagic stroke. The diagnosis and management of AIS are restricted by the short of diagnostic assays for use in the emergency setting. Recently, it has indicated that MMP-9 concentration was notably improved after stroke onset, and the MMP-9 level may associate with infarct volume, stroke severity, and functional outcome, suggesting it is a possible marker for ongoing brain ischemia. What's more, MMP-9 level act as a predictor of hemorrhage in patients treated with t-PA.

IVD Antibody Development Services Targeting MMP-9 Marker

Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in all kinds of samples such as the serum, urine, tissue preparations, and so on. IVD antibodies are extensively used for disease screening, prognosis, and therapeutic monitoring. With our versatile IVD platform, Creative Biolabs is proud to develop novel anti-MMP-9 antibody from scratch to commercial IVD kit (we can also start with provided antibody candidates). If you are interested in our services, please do not hesitate to contact us for more details.

Reference

1. Yabluchanskiy, A. (2013). “Matrix metalloproteinase-9: many shades of function in cardiovascular disease.” Physiology 28(6), 391-403.
2. Phatharajaree, W. (2007). “Matrix metalloproteinases and myocardial infarction.” Canadian Journal of Cardiology 23(9), 727-733.
3. Wagner, D. R. (2006). “Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction.” Journal of cardiac failure 12(1), 66-72.

For Research Use Only.